Edition:
United States

McKesson Corp (MCK.N)

MCK.N on New York Stock Exchange

150.85USD
24 Feb 2017
Change (% chg)

$1.88 (+1.26%)
Prev Close
$148.97
Open
$148.93
Day's High
$150.87
Day's Low
$147.87
Volume
204,308
Avg. Vol
565,954
52-wk High
$199.22
52-wk Low
$114.54

Latest Key Developments (Source: Significant Developments)

Mckesson considering separation of info tech unit, worth possibly more than $5 bln - CNBC citing DJ
Thursday, 2 Jun 2016 11:33pm EDT 

: Mckesson Corp considering separation of info tech unit, worth possibly more than $5 bln; could be spun off or merged with a rival - CNBC citing Dow Jones Further company coverage: [MCK.N] ((Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)).  Full Article

UK's CMA says investigating UK aspects of McKesson-UDG deal
Thursday, 12 May 2016 11:00am EDT 

UK'S Competition and Markets Authority(CMA): UK'S CMA says investigating UK aspects of acquisition by McKesson Corp unit AAH Pharmaceuticals of 2 units within UDG Healthcare, Masta and Sangers (Bengaluru Newsroom: +91 80 6749 1136).  Full Article

McKesson Corp - McKesson cuts 1,600 jobs to trim costs - Reuters News
Wednesday, 16 Mar 2016 09:26pm EDT 

McKesson Corp:McKesson Corp MCK.N said on Wednesday it cut 1,600 jobs, or about 4 percent of its U.S. workforce, to slash costs after the company lost some key customers. - RTRS.McKesson said in January it would review its cost structure and decided that "reductions to our workforce would be necessary to align our cost structure with our business needs," the company said in an e-mailed statement.The company said it started informing workers about the lay-offs in mid-March. McKesson also said it was offering severance benefits and outplacement services for impacted employees.As of March 2015, the company employed about 70,400 full-time workers, according to a regulatory filing.  Full Article

McKesson Corporation to buy Rexall Health from Katz Group for $2.2 bln
Wednesday, 2 Mar 2016 08:30am EST 

McKesson Corporation:To buy Rexall Health from Katz Group for $2.2 bln.Says acquisition will be funded by a mix of cash and debt.Says Mckesson intends to acquire Rexall Health's business, including approximately 470 retail pharmacies.Says expects acquisition to be modestly accretive to adjusted earnings per diluted share for fiscal 2017.Says rexall health will continue to have a management team in Canada led by jürgen schreiber.Expects acquisition to drive meaningful accretion, on a constant currency basis, to fiscal 2018 adjusted earnings per diluted share.Rexall health will in Canada led by jürgen schreiber.Says operations of rexall health will be part of mckesson's distribution solutions segment.Says Co, Katz Group announced a definitive agreement to acquire Rexall Health from Katz Group.  Full Article

McKesson Corporation signs definitive agreements to purchase Vantage Oncology, LLC
Thursday, 25 Feb 2016 08:30am EST 

McKesson Corporation:signed definitive agreements to purchase Vantage Oncology, LLC, a leading national provider of radiation oncology, medical oncology and integrated cancer care, and Biologics, Inc., an oncology pharmacy services company.The combined transactions, valued at $1.2 billion, will be funded by a mix of cash and incremental debt and are expected to close in the first quarter of Fiscal 2017, subject to customary closing conditions, including necessary regulatory clearances.Following the close of the transactions, both Vantage and Biologics will become part of McKesson's Specialty Health business.McKesson expects the combined impact of these transactions to be approximately 11 cents accretive to adjusted earnings per diluted share in Fiscal 2017.  Full Article

McKesson Corp reaffirms FY 2016 and FY 2017 EPS outlook
Wednesday, 27 Jan 2016 04:10pm EST 

McKesson Corp:Outlook for FY 2016 and FY 2017 remains the same as what company provided on January 11, 2016.Expects Adjusted Earnings per diluted share between $12.60 and $12.90 for FY 2016.Expects growth in Adjusted Earnings per diluted share for FY 2017 to be between 3% and 8%, as reported, and between 7% and 12%, excluding 48 cents of gains on disposition of two businesses and favorable discrete tax items in FY 2016.  Full Article

McKesson declares regular dividend
Wednesday, 27 Jan 2016 04:00pm EST 

McKesson Corp:Declared a regular dividend of twenty-eight cents per share on Common Stock.Payable on April 1, 2016, to stockholders of record on March 1, 2016.  Full Article

McKesson Corp revises FY 2016 EPS outlook; gives FY 2017 EPS outlook
Monday, 11 Jan 2016 08:30am EST 

McKesson Corp:Announced update to its outlook for adjusted earnings per diluted share for FY 2016, from the previous range of $12.50 to $13.00 to a new range of $12.60 to $12.90.Says updated outlook for FY 2016 reflects McKesson's expectation that operating profit derived as a result of generic pharmaceutical pricing trends will be weaker in the second half of the fiscal year compared to previous expectations.Says that it has preliminary target of 7% to 12% growth in adjusted earnings per diluted share for FY 2017.  Full Article

McKesson Corp raises FY 2016 EPS guidance
Thursday, 29 Oct 2015 07:30am EDT 

McKesson Corp:Now Expects FY 2016 Adjusted Earnings per diluted share of $12.50 to $13.00.FY 2016 EPS of $12.69 - Thomson Reuters I/B/E/S.  Full Article

McKesson announces agreement to purchase the pharmaceutical distribution division of UDG Healthcare
Friday, 18 Sep 2015 05:00am EDT 

McKesson Corporation:Announces an agreement to purchase the pharmaceutical distribution division of UDG Healthcare (UDG) based in Northern Ireland (United Drug Sangers) and the Republic of Ireland (United Drug).Says under the terms of the agreement mckesson will acquire: United Drug and United Drug Sangers, wholesale operations across the Republic of Ireland and Northern Ireland; TCP, and MASTA, UDG's travel healthcare business based in the United Kingdom.  Full Article

More From Around the Web

Fitch Rates McKesson's EUR and GBP Notes 'BBB+'; Outlook Stable

(The following statement was released by the rating agency) NEW YORK, February 13 (Fitch) Fitch Ratings has assigned 'BBB+' ratings to the EUR and GBP denominated senior unsecured notes issued by McKesson Corp. (NYSE: MCK). A full list of ratings follows at the end of the release. KEY RATING DRIVERS Stable Operations, Low Margins The credit profiles of MCK and its peers benefit from stable operating profiles and consistent cash generation. Steady pharmaceutical demand, an oligopolistic drug